BTG raises full-year guidance on acquisition, settlements and milestone
This article was originally published in Scrip
Executive Summary
On the day it expects to close its £177 million acquisition of drug delivery specialist Biocompatibles, BTG raised its guidance for full-year revenues to £108-£114 million, from £93-£97 million previously, to take account of Biocompatibles' contribution, revenues from legal settlements and a milestone related to the prostate cancer therapy abiraterone acetate.